Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Lorus Therapeutics Q3 Loss Narrows - Quick Facts

4/12/2012 5:28 PM ET

Canadian biopharmaceutical company Lorus Therapeutics Inc. (LOR.TO: Quote,LRUSF.PK) posted a narrower loss in the third quarter.

The company posted third-quarter net loss of C$1.0 million or C$0.05per share, narrower than than C$1.5 million or C$0.10 per share last year. Lorus Therapeutics attributed the wider net loss mainly to higher general and administrative, and research and development expenditures.

The company did not generate any revenues in both the quarters.

Click here to receive FREE breaking news email alerts for Lorus Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Russian Foreign Minister Sergei Lavrov warned Wednesday that Moscow would retaliate strongly if its "interests" in Ukraine are attacked. He also criticized the Ukrainian administration for relaunching its so-called anti-terrorist operation in the east of the country a day earlier. Lavrov's remarks came in an interview with Russia Today, which published excerpts of the English-language interview to While selling pressure has remained relatively subdued, stocks continue to see modest weakness in mid-day trading on Wednesday. The losses on the day come on the heels of the upward trend seen over the past several sessions. The major averages have moved roughly sideways in recent trading, lingering in the red. While a majority of Kentucky voters approve of the way Rand Paul is handling his job as Senator, the results of New York Times/Kaiser Family Foundation poll showed that voters from the Bluegrass State have a more mixed view on Paul's potential run for president in 2016.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.